CYYNF (Cynata Therapeutics) Buyback Yield %: -3.90 (As of Jun. 29, 2026)


What is Cynata Therapeutics Buyback Yield %?

Cynata Therapeutics CYYNF -95.96% Buyback Yield % is -3.90 as of Jun. 29, 2026. The stock has 1 warning sign investors should review. Among 743 Biotechnology companies, Cynata Therapeutics ranks better than 62.85% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cynata Therapeutics's current buyback yield was -3.90%.

Cynata Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Cynata Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics Buyback Yield % Chart

Cynata Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.35 0.00 -10.47 0.00 -27.43

Cynata Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -13.86 -22.47 -0.14

CYYNF vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Cynata Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cynata Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's Buyback Yield % falls into.


Cynata Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cynata Therapeutics's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.34 + 5.298) / 18.07632
=-27.43%

Cynata Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.015 + 0.089) / 35.6181
=-0.21%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -3.90 mean?
Cynata Therapeutics (CYYNF) has a Buyback Yield % of -3.90 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cynata Therapeutics and its competitors. According to the industry distribution chart, Cynata Therapeutics ranks #276 out of 743 companies in the Biotechnology industry, placing it in the top 37.1%.
Is Cynata Therapeutics' Buyback Yield % too high?
Cynata Therapeutics' current Buyback Yield % is -3.90. Based on the distribution chart, Cynata Therapeutics ranks #276 out of 743 companies in the Biotechnology industry, which is above the industry midpoint.
How does Cynata Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cynata Therapeutics ranks #276 out of 743 companies for Buyback Yield %. This puts Cynata Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cynata Therapeutics and its competitors. Cynata Therapeutics's current Buyback Yield % is -3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current Buyback Yield % of -3.90. The current Buyback Yield % is -3.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current Buyback Yield % is -3.90 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cynata Therapeutics Business Description

Other Exchanges 51S:GermanyCYP:Australia
Address 100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.